期刊文献+

骨化三醇冲击治疗对血液透析继发性甲旁亢患者疗效的影响 被引量:2

A Study of Curative Effect of Calcitriol Pulse Therapy on Hemodialysis Secondary Hyperpara-thyroidism
下载PDF
导出
摘要 【目的】研究骨化三醇冲击治疗对血液透析继发性甲状旁腺功能亢进(甲旁亢)患者甲状旁腺激素(PTH)、血钙与血磷水平的影响。【方法】将90例血液透析继发性甲旁亢患者纳入研究对象,采用随机数字表法分为观察组和对照组,每组各45例,观察组接受骨化三醇冲击剂量治疗、对照组接受骨化三醇常规剂量治疗,比较两组患者PTH、血钙与血磷水平,骨代谢指标及不良反应。【结果】①治疗后4周、8周、12周时,观察组PTH水平明显低于对照组(405.62±50.62VS514.74±61148,335.93±45.96vs441.38±56.23,241.87±39.43 vs 352.58±49.62)pg/mL,且两组相比较差异均有显著性(P〈0.05);②观察组患者的血钙水平明显高于对照组(2.49±0.35 vs 2.21±0.25)mmol/L,血磷水平均明显低于对照组(1.21±0.16 vs 1.78±0.24)mmol/L;③观察组患者的血清骨碱性磷酸酶(BALP)、骨钙素(Oc)含量均明显低于对照组[(24.59±4.95 vs 50.66±6.78)U/L,(4.49±0.62 vs 8.87±0.94)μg/L],且两组相比较差异均有显著性(P〈0.05);④观察组不良反应为2.22%,明显低于对照组17.78%,且两组相比较差异均有显著性(χ2=6.049,P〈0.05)。【结论】骨化三醇冲击治疗有助于降低PTH水平,调节血钙和血磷平衡,改善患者骨代谢,降低不良反应,提高治疗效果。 [Objective]To study the effect of calcitriol pulse therapy on hemodialysis secondary hyperpara- thyroidism and their levels of parathyroid hormone , serum calcium and serum phosphorus. [Methods] 90 ca- ses of patients with hemodialysis secondary hyperparathyroidism in our hospital were enrolled and randomly divided into two grups,the observation group and the control group, 45 cases for each them. The observation group received calcitriol pulse dosage therapy, while control group received conventional calcitriol dosage ther- apy . The results of parathyroid hormone , serum calcium and serum phosphorus , bone metabolic index and advervse reactions were compared. [Results]①parathyroid hormone:4, 8, 12 weeks after treatment, parathy- roid hormone levels of the observation group were lower than those of the control group (405.62 ±50.62 vs 514.74±61.48, 335.93±45.96 vs 441.38±56.23, 241.87±39.43 vs 352.58±49.62)pg/mL;②serum calcium and serum phosphorus., serum calcium level of the observation group was higher than that of the control group (2.49 ± 0.35 vs 2.21 ± 0.25) retool/L, and serum phosphorus level was even lower than that of the control group (1.21±0.16 vs 1.78±0.24) mmol/L;③bone metabolism index., serum BALP and OC contents of the observation group were lower than those of the control group [ (24.59 52 4.95 vs 50.66 52 6.78) U/L, (4.49 ± 0.62 vs 8 875±0.94) μg/L] ,the difference hereby was significant ( P 〈0.05) ④Adverse reactions: the obser- vation group was 2.22 %, significantly lower than the control group 17.78 %, the difference hereby was signifi- cant(χ2=6.049, P 〈0.05). [Conclusions]Caicitriol pulse therapy is helpful to reduce PTH level, regulate cal- cium and phosphorus balance, improve bone metabolism~ it's an ideal method in treating hemodialysis seconda- ry hyperparathyroidism.
作者 苏惠
出处 《医学临床研究》 CAS 2015年第8期1460-1463,共4页 Journal of Clinical Research
基金 安徽省科技厅重点科研资助项目(项目编号:12070403071)
关键词 骨化三醇/治疗应用 肾透析/副作用 甲状旁腺功能亢进症 继发性/病因学 甲状旁腺素 Caleitriol/TU Renal Dialysis/AE Hyperparathyroidism, Secondary/ET Parathy-roid Hormone
  • 相关文献

参考文献12

二级参考文献51

  • 1姜鸿,徐志宏,张凌,宋韩明,李文歌.慢性肾脏病3~5期透析前患者矿物质及骨代谢紊乱的调查分析[J].中国血液净化,2012,11(7):360-364. 被引量:43
  • 2王成,娄探奇,唐骅,陈珠江,石成钢,尹培达,余学清.常用血液净化方法对维持性血液透析患者血清甲状旁腺素的清除效果[J].中华急诊医学杂志,2005,14(1):61-63. 被引量:108
  • 3Silver J, Levi R. Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease[J]. Kidney Int Suppl, 2005,95: S8-S12.
  • 4Naveh-Many T, Neehama M. Regulation of parathyroid hor- mone mRNA stability by calcium, phosphate and uremia[J]. Curr Opin Nephrol Hypertens,2007, 16(4) : 305-310.
  • 5Block GA. Screening dialysis patients for vascular calcification [J]. Semin Dial,2010,23(3) :271-276.
  • 6Bhan I, Thadhani tL Vascular calcification and ESRD.. a hard target[J]. Clin J Am Soc Nephrol, 2009, 4 (Suppl 1 ) : S102- S105.
  • 7Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients[J]. J Bone Miner Res,2011,26(6) :1368-1376.
  • 8Moorthi RN, Moe SM. CKD-mineral and bone disorder:core curriculum 2011[J]. Am J Kidney Dis, 2011,58 (6): 1022-1036.
  • 9Moorthi RN, Moe SM. Recent advances in the noninvasive diagnosis of renal osteodystrophy[J]. Kidney Int, 2013, 180(30) : 1300-1305.
  • 10Malluche HH, Porter DS, Monier-Faugere MC, et al Differences in bone quality in low- and high turnover re nal osteodystrophy[J]. J Am Soc Nephrol, 2012,23 (3) 525-532.

共引文献50

同被引文献17

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部